Small Hospitals
Market Cap
₹16,007 ₹16,007 Cr.
P/E
107.88
PEG
6.03
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The bull case is driven by successful Delhi NCR cluster ramp and refractive surgery recovery, boosting new greenfield revenue above base projections.

The bear case is triggered by SSSG deceleration below 12% and Delhi NCR greenfield losses exceeding targets, compressing margins and reducing new facility contribution.

The growth mix shifts from mature base SSSG to new greenfield output, concentrating execution risk on the ambitious 60-facility-per-year expansion plan.

Key Ratios

Debt to Equity
Debt to Equity
0.08
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
1.66 %
Institutions
Institutions
65.68 %
Market cap
Market cap
16,007 Cr
No. of Shareholders
No. of Shareholders
42,492
OPM (%)
OPM (%)
27.74 %
PE
PE
107
Prom Holding
Prom Holding
32.34 %
ROCE (%)
ROCE (%)
10.00
ROE (%)
ROE (%)
6.58
Sales
Sales
2,206 Cr
  • Dr. Agarwal's Health
  • Apollo Hospital Ent.
  • Max Healthcare Inst.
Last updated on 13 Aug 2026
  • Dr. Agarwal's runs India's largest eye-care chain by revenue per CRISIL: 288 India plus 19 Africa facilities on hub-and-spoke; surgeries/consults ~78% of revenue, optical/pharma rest.
  • Earnings anchored by mature centres up ~14%; cataract ~73% of surgeries with high-end share rising.
  • Per management staying premium, not commodity; 222 facilities since FY22.
  • Organic build-out underway, North priority; tertiary hospitals in Thane, Chennai and Cathedral Road advancing; forward capex ₹380–400Cr FY27.
  • Mid-ramp on greenfield blitz; FY27 growth guided ~20% with stable margins hinges on Delhi-NCR and new centres hitting breakeven.
  • Lease liabilities ₹818Cr plus ₹333Cr put option pressure cash conversion.
  • AEHL Cathedral Road facility by Q2 FY27
    large subsidiary facility adds revenue guided ~30% YoY once running.
  • Thane CMS hospital 1 Oct 2026
    large tertiary capacity comes online, then 12–18 month stabilisation to breakeven.
  • FY27 guidance delivery quarterly through FY27
    60 greenfield adds with margins holding 28.5–29% and growth at ~20%.
  • AEHL merger completion Q3–Q4 FY27
    listed subsidiary consolidates and delists.
  • Delhi-NCR ramp 12–18 months to breakeven
    adds 7–8 centres; ₹30Cr FY26 losses narrow toward breakeven.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
402
52W Range
High
568
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Payment Mode

Operational Metrics

    Select a Metric

    Peer Comparison

    FAQs on Dr. Agarwal's Health Care Ltd. Business

    Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lens and accessories, and eye care related pharmaceutical products. It endeavours to address all the needs of its patients in their eye treatment journey through a network.

    Dr. Agarwal's Health major competitors are Apollo Hospital Ent., Max Healthcare Inst., Fortis Healthcare, Global Health, Narayana Hrudayalay., Krishna Inst.Medi, Aster DM Quality.
    Market Cap of Dr. Agarwal's Health is ₹15,705 Crs.
    While the median market cap of its peers are ₹64,587 Crs.

    Dr. Agarwal's Health seems to be less financially stable compared to its competitors.
    Altman Z score of Dr. Agarwal's Health is 6.63 and is ranked 6 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Feb May May Aug Oct Dec
    Investor Presentation Feb May Aug May Aug Oct Dec
    Conference Call Feb May Aug Mar Jun Nov Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material